Israel · Delayed Price · Currency is ILS · Price in ILA Scinai Immunotherapeutics Statistics
Total Valuation
TLV:BVXV has a market cap or net worth of ILS 3.21 million. The enterprise value is 21.66 million.
| Market Cap | 3.21M |
| Enterprise Value | 21.66M |
Important Dates
The next estimated earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +140.86% |
| Shares Change (QoQ) | +23.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.84 |
| PB Ratio | 0.09 |
| P/TBV Ratio | 0.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.35 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.54 |
| Interest Coverage | -17.92 |
Financial Efficiency
Return on equity (ROE) is -29.19% and return on invested capital (ROIC) is -38.62%.
| Return on Equity (ROE) | -29.19% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -38.62% |
| Return on Capital Employed (ROCE) | -56.64% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 85,177 |
| Profits Per Employee | -222,625 |
| Employee Count | 45 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.07% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +13.07% |
| 50-Day Moving Average | 48.03 |
| 200-Day Moving Average | 63.36 |
| Relative Strength Index (RSI) | 53.18 |
| Average Volume (20 Days) | 1,402,253 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, TLV:BVXV had revenue of ILS 3.83 million and -10.02 million in losses. Loss per share was -3.58.
| Revenue | 3.83M |
| Gross Profit | -12.62M |
| Operating Income | -26.65M |
| Pretax Income | -10.02M |
| Net Income | -10.02M |
| EBITDA | -21.84M |
| EBIT | -26.65M |
| Loss Per Share | -3.58 |
Balance Sheet
The company has 9.36 million in cash and 11.04 million in debt, with a net cash position of -1.68 million.
| Cash & Cash Equivalents | 9.36M |
| Total Debt | 11.04M |
| Net Cash | -1.68M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 37.13M |
| Book Value Per Share | 5.48 |
| Working Capital | 2.93M |
Cash Flow
In the last 12 months, operating cash flow was -20.35 million and capital expenditures -56,831, giving a free cash flow of -20.41 million.
| Operating Cash Flow | -20.35M |
| Capital Expenditures | -56,831 |
| Depreciation & Amortization | 4.56M |
| Net Borrowing | n/a |
| Free Cash Flow | -20.41M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -695.30% |
| Pretax Margin | -261.37% |
| Profit Margin | -261.37% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:BVXV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -140.86% |
| Shareholder Yield | -140.86% |
| Earnings Yield | -312.37% |
| FCF Yield | -636.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TLV:BVXV has an Altman Z-Score of -10.89. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.89 |
| Piotroski F-Score | n/a |